tipifarnib has been researched along with tamibarotene in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 198 | 10 | 105 |
| Protein | Taxonomy | tipifarnib (IC50) | tamibarotene (IC50) |
|---|---|---|---|
| Chain A, PROTEIN (CRABP-I) | Bos taurus (cattle) | 0.14 | |
| Chain A, PROTEIN (CRABP-II) | Homo sapiens (human) | 0.14 | |
| Chain A, PROTEIN (CRABP-II) | Homo sapiens (human) | 0.14 | |
| Retinoic acid receptor alpha | Homo sapiens (human) | 0.078 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
1 review(s) available for tipifarnib and tamibarotene
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |